Kaneda, Hiroyasu http://orcid.org/0000-0002-7696-2391
Sawa, Kenji
Daga, Haruko
Okada, Asuka
Nakatani, Yuki
Atagi, Shinji
Okishio, Kyoichi
Tani, Yoko
Matsumoto, Yoshiya
Ogawa, Koichi
Nakahama, Kenji
Izumi, Motohiro
Mitsuoka, Shigeki
Kawaguchi, Tomoya
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 17 May 2021
Accepted: 24 June 2021
First Online: 2 July 2021
Declarations
:
: The study was approved by the institutional review board of each participating institution and was conducted in compliance with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice Guideline, and applicable local regulations.
: Informed consent was obtained from all individual participants included in the study.
: Dr. Kaneda reports grants from Eli Lilly, during the conduct of the study; personal fees from Chugai, Astrazeneca, Novartis Pharma, Bristol-Myers Squibb, Ono, Boehringer Ingelheim, MSD, Taiho, Pfizer, Nippon KAYAKU, and Merck, outside the submitted work. Dr. Sawa reports personal fees from Chugai Pharmaceutical, Daiichi Sankyo, and Nippon Boehringer Ingelheim, all outside the submitted work. Dr. Daga reports personal fees from Chugai, and Ono; grants from Astrazeneca, all outside the submitted work. Dr. Atagi reports grants and personal fees from AstraZeneca, Ono, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, MSD, Eli Lilly, Chugai, and Merck; grants and non-financial support from F. Hoffmann-La Roche; personal fees from Hisamitsu, Kyowa Hakko Kirin, Novartis Pharma, and Thermo Fisher Scientific, all outside the submitted work. Dr. Mitsuoka reports personal fees from Ono, Bristol-Myers Squibb, and Kyowa Hakko Kirin; grants from Taiho Pharmaceutical, all outside the submitted work. Dr. Kawaguchi reports grants and personal fees from Chugai Pharma, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, and Bristol-Myers Squibb Japan; grants, personal fees and non-financial support from Eli Lilly; personal fees from Astra Zeneca, MSD Oncology, Pfizer, Novartis, and Astellas Pharma; grants from Daiichi Sankyo,all outside the submitted work. All remaining authors have declared no conflicts of interest.